3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
24
Prostatic Neoplasms, Castration-Resistant
4
Prostatic Diseases
3
Neoplasm Metastasis
3
Metastatic Castration-resistant Prostate Cancer
3
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Adenocarcinoma
2
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Non-metastatic Castration-resistant Prostate Cancer
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
High-Risk Localized Prostate Cancer
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Solid Tumor
1
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
High-Risk Localized Prostate Cancer
×
darolutamide
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled